Accuray Incorporated (ARAY)vsNovartis AG ADR (NVS)
ARAY
Accuray Incorporated
$3.08
-3.75%
HEALTHCARE · Cap: $16.72M
NVS
Novartis AG ADR
$160.32
-0.04%
HEALTHCARE · Cap: $303.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 14172% more annual revenue ($57.36B vs $401.95M). NVS leads profitability with a 17.5% profit margin vs -12.2%. NVS appears more attractively valued with a PEG of 3.84. NVS earns a higher WallStSmart Score of 48/100 (D+).
ARAY
Hold37
out of 100
Grade: F
NVS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ARAY.
Margin of Safety
-69.8%
Fair Value
$95.76
Current Price
$160.32
$64.56 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Strong operational efficiency at 34.3%
Every $100 of equity generates 27 in profit
Generating 4.8B in free cash flow
Areas to Watch
Trading at 8.8x book value
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ARAY
ARAY has a balanced fundamental profile.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bear Case : ARAY
The primary concerns for ARAY are Price/Book, Market Cap, Piotroski F-Score. Debt-to-equity of 2.56 is elevated, increasing financial risk.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Key Dynamics to Monitor
ARAY profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.
ARAY carries more volatility with a beta of 1.42 — expect wider price swings.
NVS is growing revenue faster at 4.7% — sustainability is the question.
NVS generates stronger free cash flow (4.8B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (48/100 vs 37/100), backed by strong 17.5% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Accuray Incorporated
HEALTHCARE · MEDICAL DEVICES · USA
Accuray Incorporated designs, develops and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa and the rest of the Asia Pacific region. The company is headquartered in Sunnyvale, California.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?